Header Forschung

Publications

1. Heining C, Horak, P, Uhrig S, Codó P, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S,* Glimm H.* NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov, in press.

2. Terziev D, Hutter B, Klink B, Stenzinger A, Stögbauer F, Glimm H, Fröhling S, Wickenhauser C, Jordan K, Hurtz HJ, Müller LP, Rüssel J, Weber T. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma. Eur J Haematol, in press.

3. Perera-Bel J, Hutter B, Heining C, Bleckmann A, Fröhlich M, Fröhling S, Glimm H, Brors B, Beißbarth T. From somatic variants towards precision oncology: evidence-driven reporting of treatment options in molecular tumor boards. Genome Med 10:18, 2018.

4. Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig C, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun 9:144, 2018.

5. Czink E, Kloor M, Goeppert B, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Jäger D, Springfeld C. Successful immune checkpoint blockade in a patient with advanced stage microsatellite unstable biliary tract cancer. Cold Spring Harb Mol Case Stud 3:a001974, 2017.

6. Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T. Genomics of immunotherapy-associated hyperprogressors. Clin Cancer Res 23:6374-6375, 2017.

7. Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. Eur J Cancer 83:142-145, 2017.

8. Gröschel S,* Bommer M,* Hutter B, Budczies J, Bonekamp D, Heining C, Fröhlich M, Hübschmann D, Geörg C, Richter D, Pfarr N, Pfütze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S. Integration of genomics and histology reveals diagnosis and effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud 2:a001180, 2016.

9. Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Fröhling S, Penzel R, Enk A, Hassel JC. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol 176:498-502, 2017.

10. Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W,* Glimm H,* Fröhling S.* Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. Ann Oncol 8:142-148, 2017.

11. Bochtler T, Fröhling S, Weichert W, Endris V, Thiede C, Hutter B, Hundemer M, Ho AD, Krämer A. Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. Cold Spring Harb Mol Case Stud 2:a001123, 2016.

12. Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S. Targeting FGFR1 for treatment of soft-tissue sarcoma. Clin Cancer Res 23:962-973, 2017.

13. Czink E, Heining C, Weber TF, Lasitschka F, Schemmer P, Schirmacher P, Weiss KH, Glimm H, Brors B, Weichert W, Jäger D, Fröhling S,* Springfeld C.* Durable remission under dual HER2 blockade with trastuzumab and pertuzumab in a patient with metastatic gallbladder cancer. Z Gastroenterol 54:426-430, 2016.

14. Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H,* Brummer T,* Fröhling S.* Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia 30:937-946, 2016.

15. Husedzinovic A, Ose D, Schickhardt C, Fröhling S, Winkler EC. Stakeholders’ perspectives on biobank-based genomic research: systematic review of the literature. Eur J Hum Genet 23:1607-1614.


Reviews

1. Heining C, Horak P, Gröschel S, Glimm H, Fröhling S. Personalized oncology. Radiologe 57:804-811, 2017.

2. Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H,* Fröhling S.* Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer 141:877-886, 2017.

3. Horak P, Fröhling S, Glimm H. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open 1:e000094, 2016.